Nektar to acquire Aerogen

NKTR will acquire AEGN for about $32 million in cash and stock, or $0.75 per share. Aquilo Partners advised AEGN in the deal, which is expected to close next quarter. AEGN develops and markets nebulizers and inhalers and is developing inhaled therapeutics, including aerosolized amikacin, which is in Phase II testing for ventilator-associated pneumonia (VAP). The compound has Fast Track designation from FDA. ...